Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Says its BTK Inhibitor Out-Performs Janssen’s Imbruvica

publication date: Dec 14, 2022

BeiGene, a Beijing based biopharma, announced that its BTK inhibitor, Brukinsa (zanubrutinib), was more effective than Janssen’s Imbruvica (ibrutinib), the current standard of care, in a head-to-head leukemia trial. In a Phase III trial, Brukinsa patients saw a 35% lower risk of disease progression or death compared to Imbruvica. At the 24-month follow-up, progression-free survival rates were 78.4% for Brukinsa verses 65.9% for Imbruvica. The ALPINE trial enrolled patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160; SHA: 688235)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital